Recombinant Immunotoxins for Treating Cancer
Targeted antibody therapy represents a promising approach for the treatment of cancer. However, antibodies that bind to cancer cells are often, by themselves, not cytotoxic. Recombinant immunotoxins (RITs) are chimeric proteins composed of the variable fragment (Fv) of a monoclonal antibody fused to a portion of a powerful bacterial toxin. The Fv replaces the cell-binding domain of the toxin and directs the toxin to cancer cells that express an internalizing target antigen. RITs are very potent and are able to kill cells that are resistant to standard chemotherapy. Results from clinical trials indicate that RITs that are designed to combine antibody selectivity with toxin cell-killing potency will be useful additions to cancer therapy.
- 感染性疾病流行过程的基本条件
- 犬葡萄糖依赖性胰岛素释放多肽(GIP)酶联免疫分析
- Technical and Ethical Limitations in Making Human Monoclonal Antibodies (An Overview)
- Purification and Characterization of His-Tagged Antibody Fragments
- Periodate Treatment of Fixed Cell Plates
- Microarray Technology for Analysis of MicroRNA Expression in Renal Biopsies of Lupus Nephritis Patients
- Methanol Fixation for Immunofluorescence
- Isolation of M. tuberculosis RNA from Sputum
- From Vaccine Research to Manufacture: A Guide for the Researcher
- Detection of Cytokine- and Chemokine-Expressing Cells at the Single Cell Level